Call our hotline now 1-877-973-4221

Catalyst Pharmaceutical Partners And The National Institute On Drug Abuse Plan To Initiate U.S. Phase II(b) Clinical … (Medical News Today)

More info…
Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst’s formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran’s Administration …

drug addiction treatment

Leave a Reply